An Open Label Study to Evaluate The Efficacy And Safety Of Sofosbuvir/GS-5816 Fixed Dose Combination With Ribavirin For 24 Weeks In Chronic HCV Infected Subjects Who Participated In A Prior Gilead Sponsored HCV Treatment Study
Phase of Trial: Phase II
Latest Information Update: 01 Aug 2017
At a glance
- Drugs Sofosbuvir/velpatasvir (Primary) ; Ribavirin
- Indications Hepatitis C
- Focus Adverse reactions; Therapeutic Use
- Sponsors Gilead Sciences
- 07 Oct 2016 Status changed from active, no longer recruiting to completed.
- 17 Apr 2016 Interim results (n=41) presented at The International Liver Congress™ 2016.
- 01 Dec 2015 Status changed from recruiting to active, no longer recruiting, as reported by ClinicalTrials.gov.